<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Schistosomiasis and glomerular disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Schistosomiasis and glomerular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Schistosomiasis and glomerular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cristiane Bitencourt Dias, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human schistosomiasis is caused by infection with <em>Schistosoma haematobium</em>,<em> S. mansoni</em>, <em>S. japonicum</em>, <em>S. mekongi</em>, or <em>S. intercalatum</em>. The three species most frequently infecting humans are <em>S. mansoni</em>, which is endemic in Latin America, <em>S. japonicum</em> in China and East Asia, and <em>S. haematobium</em> in Africa. The kidneys are important targets of schistosomal infection. There are several patterns of kidney involvement in schistosomiasis, including the upstream sequelae of lower urinary tract pathology [<a href="#rid1">1</a>], glomerulonephritis with different immune-mediated pathways [<a href="#rid2">2</a>], tubulointerstitial nephritis [<a href="#rid3">3</a>], and oxidant-stress-mediated tubular injury [<a href="#rid4">4,5</a>]. Glomerular disease associated with schistosomiasis will be discussed here. Other issues related to schistosomiasis are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5682.html" rel="external">"Schistosomiasis: Diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Like many other helminthic diseases [<a href="#rid6">6</a>], schistosomiasis may produce a broad spectrum of glomerular pathology. The incidence is unknown since many cases are subclinical or resolve spontaneously. In a village in Upper Egypt, for example, where <em>S. haematobium</em> was newly introduced as a result of changing irrigation methods, the majority of those who acquired the infection developed self-limited nephrotic-range proteinuria with biopsy-confirmed mesangioproliferative glomerulonephritis [<a href="#rid7">7,8</a>]. Similar glomerular lesions have also been described with recent <em>S. mansoni</em> or <em>S. japonicum</em> infection and usually resolve with antiparasitic treatment.</p><p>By contrast, persistent or progressive glomerular disease develops in approximately 10 to 15 percent of patients who usually have hepatic fibrosis due to chronic infection with <em>S. mansoni</em> (and occasionally <em>S. haematobium</em>) [<a href="#rid2">2,9-12</a>]. Despite the global schistosomiasis control programs, new cases of schistosomal glomerulopathy continue to be reported [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H7923462"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Several observations support a pathogenic role for schistosomal infection in the development of glomerular disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular lesions, similar to those described in humans, have been induced by experimental infection of many small and large animals [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies against schistosomal antigens can often be eluted from the glomeruli of affected animals [<a href="#rid15">15</a>] and humans [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Schistosomal antigens have been detected in the glomeruli by indirect immunofluorescence (in which fluoresceinated anti-schistosomal antibodies are incubated with the kidney tissue) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are several observations of an association between schistosomal infection and clinical glomerular disease, as described above [<a href="#rid2">2,7,9,11,12,18,19</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p>A number of disease mechanisms are thought to contribute to the pathogenesis of schistosomal glomerular disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune complex formation – Deposition in the mesangium of circulating antigens derived from the adult worm and eggs, with subsequent formation of immunoglobulin M (IgM) and G (IgG) immune complexes, is considered the main mechanism of glomerular disease. Schistosomiasis can produce hepatic fibrosis, which impairs the clearance of these antigens from the portal blood [<a href="#rid20">20</a>]. These find their way to the systemic circulation through intrahepatic and extrahepatic portosystemic shunts associated with hepatic fibrosis. This mechanism is thought to be responsible for the development of membranoproliferative glomerulonephritis in patients with schistosomal infection.</p><p></p><p class="bulletIndent1">Treatment of the parasitic infection does not end the process of progression of the glomerular disease. Autoimmune factors may also be triggered and sustain the lesions. Because of this, infected patients as well as experimental animals may develop antinuclear antibodies (ANA), rheumatoid factor, cryoglobulins, and antiphospholipid antibodies [<a href="#rid14">14,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct podocyte injury – T cell dysfunction and the production of cytokines that promote podocyte injury are thought to play a role in the pathogenesis of nephrotic syndrome in patients with schistosomal infection [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin A (IgA) production – Schistosomiasis is associated with increased local production of mucosal IgA. In late stages of infection, interleukin (IL) 10 induces a significant increase in the expression of IgA on circulating B lymphocytes, which suggests a preferential switching of B lymphocyte generation to IgA predominance [<a href="#rid23">23-25</a>]. The circulating immunoglobulin profile is characterized by significant augmentation of IgA subsets [<a href="#rid26">26</a>]. Impaired clearance of IgA due to the associated hepatic fibrosis leads to an increase in circulating IgA [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis", section on 'Associated conditions'</a>.)</p><p></p><p class="bulletIndent1">The deposition of IgA is in mesangial, subendothelial, subepithelial, and peritubular locations, suggesting an important pathogenic role for this immunoglobulin  (<a class="graphic graphic_figure graphicRef89548" href="/d/graphic/89548.html" rel="external">figure 1</a>) [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coinfection – Coinfection with other microbial agents, particularly <em>Salmonella</em> and hepatitis B virus (HBV) and/or hepatitis C virus (HCV), enhances and modifies the glomerular structural and/or functional changes associated with schistosomiasis [<a href="#rid19">19,28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic factors – Genetics appear to be important in the susceptibility to schistosomal infection [<a href="#rid30">30</a>], progression to hepatic fibrosis [<a href="#rid31">31</a>], initiation of glomerulonephritis [<a href="#rid32">32</a>], and the pattern of glomerular lesions [<a href="#rid33">33,34</a>]<em>.</em></p><p></p><p>Differences in the schistosomal strains and the severity of infection may explain geographic variations in the prevalence of schistosomal glomerulopathy [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICOPATHOLOGIC MANIFESTATIONS</span><span class="headingEndMark"> — </span>The glomerular manifestations and histologic correlations are discussed in this section. Other clinical features associated with schistosomiasis are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H972611"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>As noted above, asymptomatic and self-limited glomerular disease may be relatively common in patients with schistosomal infection. (See <a class="local">'Epidemiology'</a> above.)</p><p>However, patients with schistosomal glomerulopathy can present with clinical and laboratory features that vary depending upon the glomerular histologic pattern of the patient. As an example, patients with membranoproliferative glomerulonephritis (class III), the most common histologic form (71 percent of cases in one series [<a href="#rid14">14</a>]), frequently present with features of both nephrotic and nephritic syndrome. Such patients generally have hematuria (82 percent), hypertension (71 percent), and low serum complement C3 levels (65 percent). (See <a class="local">'Histologic classification'</a> below.)</p><p>Nephrotic syndrome (without nephritic syndrome) can be the presentation in patients with a histologic pattern of focal segmental glomerulosclerosis (FSGS; class IV), or, less commonly, minimal change disease or membranous nephropathy [<a href="#rid14">14,36</a>].</p><p>Unlike other causes of nephrotic syndrome, despite severe hypoproteinemia, serum lipid concentrations are usually low due to associated nutritional deficiency and hepatic dysfunction. (See  <a class="medical medical_review" href="/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a>.) </p><p>Patients who do <strong>not</strong> have the common nephrotic-nephritic or nephrotic presentation mentioned above may present with other kidney manifestations, including (see <a class="local">'Histologic classification'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated non-nephrotic proteinuria with normal glomerular filtration rate (GFR; such patients are asymptomatic and therefore incidentally identified); these patients will have class I by histology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute glomerulonephritis with hematuria and heavy proteinuria (such patients have been described with recent-onset <em>S. haematobium</em> infection); these patients will have class I or II by histology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotic syndrome in combination with systemic manifestations of coinfection with <em>Salmonella</em> (class II) or hepatitis C virus (HCV; class VI) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>End-stage kidney disease (ESKD).</p><p></p><p>Most asymptomatic patients with incidentally discovered non-nephrotic proteinuria will recover with antiparasitic treatment. By contrast, most symptomatic patients will have progressive kidney disease and develop ESKD or die from severe nutritional deficiency, intercurrent infection, or other sequelae of hepatic fibrosis.</p><p class="headingAnchor" id="H2351877895"><span class="h2">Coinfection</span><span class="headingEndMark"> — </span>In regions where schistosomiasis is endemic, patients may be coinfected with other pathogenic organisms, leading to significant clinical sequelae. Infections that may modify the kidney manifestations of schistosomiasis include <em>Salmonella</em>, hepatitis B virus (HBV), HCV, and HIV. In addition, coinfection with papilloma virus seems to have a pathogenic role in schistosomal (bilharzial) bladder cancer [<a href="#rid37">37</a>]. Coinfection with tuberculosis [<a href="#rid38">38</a>], plasmodium [<a href="#rid39">39,40</a>], filarial [<a href="#rid41">41</a>], or other parasites may have important clinical implications, but kidney involvement with these organisms has not been reported [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H6911270"><span class="h3">Salmonella coinfection</span><span class="headingEndMark"> — </span>Patients with <em>Salmonella</em> coinfection may present with an acute febrile illness, arthralgias, myalgias, rash, and other signs and symptoms of salmonellosis [<a href="#rid30">30,42,43</a>]. (See  <a class="medical medical_review" href="/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology"</a> and  <a class="medical medical_review" href="/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Such patients frequently have a rapid-onset nephrotic syndrome and an active urine sediment, including red and white cell casts. The kidney function may be impaired due to sepsis and hypovolemia. Serum complement C3 is typically reduced due to alternative pathway activation by bacterial endotoxin. Patients may also have positive serological tests for syphilis, rheumatoid factor, anti­nuclear antibodies, and anti-DNA antibodies [<a href="#rid18">18</a>]. The disease is reversible with combined antiparasitic and antibiotic therapy [<a href="#rid44">44</a>].</p><p>The kidney histology in these patients is described below. (See <a class="local">'Histologic classification'</a> below.)</p><p class="headingAnchor" id="H2351877910"><span class="h3">Hepatitis B virus (HBV) coinfection</span><span class="headingEndMark"> — </span><em>Schistosoma</em> and HBV coinfection has deleterious effects on the liver, leading to the rapid onset and progression of cirrhosis to hepatocellular failure or carcinoma. HBV infection produces kidney manifestations that may be superimposed upon those due to schistosomiasis. (See  <a class="medical medical_review" href="/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection"</a>.)</p><p class="headingAnchor" id="H2351877925"><span class="h3">Hepatitis C virus (HCV) coinfection</span><span class="headingEndMark"> — </span>HCV coinfection is extremely common in patients with hepatosplenic schistosomiasis. In most patients, HCV infection seems to have been acquired via administration of unhygienic parenteral therapies for schistosomiasis. Like HBV, HCV accelerates the progression of cirrhosis and development of hepatocellular carcinoma (see  <a class="medical medical_review" href="/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a>). In addition, some of the kidney manifestations may be explained by superimposition and exacerbation of schistosomal and HCV-associated lesions [<a href="#rid19">19</a>]. (See <a class="local">'Histologic classification'</a> below.)</p><p class="headingAnchor" id="H2351877940"><span class="h3">HIV coinfection</span><span class="headingEndMark"> — </span>Schistosomiasis has been documented to increase the replication and infectivity of HIV [<a href="#rid45">45</a>] and augment its impact on kidney function [<a href="#rid28">28</a>]. However, the specific impact of HIV coinfection on schistosomal glomerular disease is unclear. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a>.)</p><p class="headingAnchor" id="H972653"><span class="h2">Histologic classification</span><span class="headingEndMark"> — </span>The African Association of Nephrology (AFRAN) has endorsed a classification of schistosomal glomerulopathies into five categories based upon the prevailing histopathological lesions [<a href="#rid2">2</a>]; a sixth category was proposed later to encompass the lesions associated with HCV coinfection  (<a class="graphic graphic_picture graphicRef88448" href="/d/graphic/88448.html" rel="external">picture 1</a>) [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Class I is mesangial proliferative glomerulonephritis, resulting from deposition of parasitic antigens and antibodies. Patients with class I schistosomal glomerulopathy are most often asymptomatic and are discovered incidentally when a urinalysis reveals mild proteinuria and/or microhematuria. GFR is unaffected. Such patients usually have a benign, self-limited course upon eradication of infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class II is an exudative glomerulonephritis associated with <em>Salmonella</em> infection. Light microscopy shows neutrophils and monocytes in the glomerulus, and immunofluorescence microscopy reveals deposition of immunoglobulin G (IgG) and complement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class III is a membranoproliferative glomerulonephritis (MPGN), usually reported in White patients, and class IV is a focal proliferative/sclerosing lesion typically seen in Black patients. These classes constitute the vast majority of the observed kidney lesions in patients with schistosomal glomerulopathy. They can occur in the hepatosplenic or intestinal form of the disease. Why Black patients preferentially develop the class IV sclerosing lesion is unclear, but it may be related to genetic factors such as polymorphisms in <em>APOL1 </em>[<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/d/html/3580.html" rel="external">"Noncirrhotic portal hypertension"</a> and  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class V is renal amyloidosis of the AA type, which results from chronic inflammation due to persistent infection. Such patients present with significant proteinuria, including the nephrotic syndrome, and reduced GFR. The course and prognosis of this category are similar to those in secondary amyloidosis due to other causes. (See  <a class="medical medical_review" href="/d/html/3120.html" rel="external">"Renal amyloidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class VI describes the extensive pathology in patients with <em>Schistosoma</em>/HCV coinfection. The glomerular lesion includes mesangial proliferation, amyloid deposition, fibrinoid necrosis, cellular apoptosis, and capillary thrombosis (all features present simultaneously). In addition, immune complexes and cryoglobulins are deposited in the glomeruli. Affected patients are grossly edematous, hypertensive, severely undernourished, and progress rapidly to ESKD. Many patients succumb to intercurrent infection even before reaching ESKD.</p><p></p><p>Some patients with schistosomiasis and heavy proteinuria are found to have membranous nephropathy (MN) [<a href="#rid46">46</a>]. However, this has not been included in the AFRAN classification owing to the lack of evidence for a pathogenic link [<a href="#rid12">12,47</a>].</p><p class="headingAnchor" id="H371248751"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>This section presents the diagnosis of schistosomal glomerulopathy. The diagnosis of schistosomiasis in general and the evaluation of infected patients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5682.html" rel="external">"Schistosomiasis: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a>.)</p><p>The diagnosis of schistosomal glomerulopathy begins with clinical suspicion in a patient presenting with kidney disease who has known <em>S. mansoni</em> infection, exposure to an endemic area, or clinical evidence of chronic hepatosplenic schistosomiasis. If an exposed patient is not known to have acquired infection, schistosomiasis should be documented. Patients with schistosomiasis and kidney disease sparing the lower urinary tract should have a kidney biopsy. In addition, it is important to evaluate these patients for coinfection with <em>Salmonella</em>, hepatitis C virus (HCV), and hepatitis B virus (HBV). (See  <a class="medical medical_review" href="/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology"</a> and  <a class="medical medical_review" href="/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a>.)</p><p>Even with documentation of schistosomal infection and a kidney biopsy consistent with schistosomal glomerulopathy, the diagnosis is essentially circumstantial. A definitive diagnosis, which is rarely obtained, requires identification of parasitic antigens in the glomeruli. Glomerular staining for schistosomal antigens is only available in specialized laboratories and is therefore primarily a research technique.</p><p class="headingAnchor" id="H6912030"><span class="h2">Documentation of schistosomal infection</span><span class="headingEndMark"> — </span>Stool and/or urine microscopy is rarely useful in making the diagnosis of schistosomiasis in patients with kidney disease since glomerulopathy is a late complication that usually occurs after the worms have ceased laying eggs. Rather, infection is typically diagnosed in such patients with either serology or a rectal submucosal biopsy (or liver biopsy if indicated for another reason). However, in a study of 24 patients with glomerulopathy associated with schistosomiasis, diagnosis of the parasite in nearly all patients was possible by finding eggs in the stool [<a href="#rid14">14</a>]. Highly specific nucleic acid tests (NATs) are available in research laboratories but are awaiting clinical application in endemic areas.</p><p>There are many clinically applicable serological tests with variable sensitivity and specificity [<a href="#rid48">48</a>]. These target either circulating antibodies or parasitic antigens. The most reliable serological test detects circulating antibodies against schistosomal microsomal antigens by an enzyme-linked immunosorbent assay using the Falcon assay screening test (FAST-ELISA) [<a href="#rid49">49</a>]. Microsomal antigens are species specific and can therefore differentiate <em>S. mansoni</em> adult worm microsomal antigens (MAMAs) from those of <em>S. hematobium</em> (HAMAs) or <em>S. japonicum</em> (JAMAs).</p><p>Circulating schistosomal antigens can be directly detected by monoclonal antibodies. The most frequently targeted are the schistosomal gut antigens, which are responsible for the glomerular immune deposits [<a href="#rid50">50</a>]. In contrast to antibody-based tests, detection of circulating parasitic antigens indicates ongoing active infection.</p><p>Laboratories that lack the facilities to perform serologic tests often use a high rectal submucosal biopsy to demonstrate <em>S. mansoni</em> ova. Old, trapped eggs may be seen and are often calcified  (<a class="graphic graphic_picture graphicRef88449" href="/d/graphic/88449.html" rel="external">picture 2</a>).</p><p class="headingAnchor" id="H6912038"><span class="h2">Role of kidney biopsy</span><span class="headingEndMark"> — </span>A kidney biopsy is usually necessary unless the kidney disease is mild and stable:</p><p class="bulletIndent1"><span class="glyph">●</span>A kidney biopsy may be deferred in a patient who presents with mild proteinuria (eg, less than 1 g/day), with or without hematuria, a normal glomerular filtration rate (GFR), and known schistosomiasis. Such patients should be reevaluated after antiparasitic therapy, and a kidney biopsy may be performed if the kidney disease is persistent or progressive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other patients with suspected schistosomal glomerulopathy should undergo kidney biopsy to exclude other forms of glomerular disease. In addition, a kidney biopsy is useful for classification (as noted above), which may influence management and inform prognosis  (<a class="graphic graphic_picture graphicRef88448" href="/d/graphic/88448.html" rel="external">picture 1</a>). (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Histologic classification'</a> above.)</p><p></p><p class="headingAnchor" id="H6912250"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Patients with chronic hepatosplenic schistosomiasis and hepatic fibrosis are at high risk for developing glomerulopathy, even after effective antiparasitic therapy  (<a class="graphic graphic_figure graphicRef88447" href="/d/graphic/88447.html" rel="external">figure 2</a>). (See <a class="local">'Pathogenesis'</a> above.)</p><p>Thus, although data are few, we suggest that such patients without known kidney disease be screened, on an annual basis, with urine dipstick testing (for proteinuria and hematuria) and measurement of serum creatinine. If an abnormal urine dipstick is confirmed after repeat testing, the urine sediment should be examined and proteinuria should be quantified with a urine protein-to-creatinine ratio.</p><p class="headingAnchor" id="H6912046"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Because the kidney presentation of schistosomal glomerulopathy is variable and nonspecific, the differential diagnosis includes many primary and secondary glomerular diseases. (See  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>Schistosomal glomerulopathy is usually distinguished by the documentation of schistosomiasis combined with consistent histologic findings. However, the kidney biopsy may suggest that the kidney disease is not due to schistosomiasis. In addition, abnormal serologic tests (such as low complement levels) are uncommon in patients with schistosomal glomerulopathy unless there is coinfection with <em>Salmonella</em>, hepatitis C virus (HCV), or hepatitis B virus (HBV).</p><p>Schistosomal glomerulopathy may also be confused with cirrhotic glomerulopathy (usually characterized by mild microhematuria and proteinuria) and with primary IgA nephropathy; both disorders, like schistosomal glomerulopathy, are characterized by glomerular IgA deposition [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Although patients with cirrhotic glomerulopathy have chronic liver disease, they rarely develop nephrotic syndrome, seldom progress to end-stage kidney disease (ESKD), and do not have extrahepatic manifestations of chronic schistosomal disease. In addition, subendothelial IgA deposits are frequent in cirrhotic glomerulopathy but are rarely seen in schistosomal glomerulopathy [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although primary IgA nephropathy can result in the nephrotic syndrome and ESKD, such patients do not have hepatic fibrosis.</p><p></p><p class="headingAnchor" id="H4"><span class="h1">THERAPY AND PROGNOSIS</span><span class="headingEndMark"> — </span>Therapy of schistosomiasis-associated glomerular disease centers around treatment of the underlying helminthic infection as well as coinfections. Other factors contributing to the patient's morbidity, such as undernutrition and intercurrent infection, must be addressed. However, the prognosis varies according to the histologic class. (See <a class="local">'Histologic classification'</a> above.)</p><p>Immunosuppressive therapy is not warranted in most patients with this disease [<a href="#rid42">42,49</a>], except in some patients with class VI disease who have life-threatening cryoglobulinemia. (See <a class="local">'Class VI'</a> below.)</p><p class="headingAnchor" id="H15644814"><span class="h2">Class I</span><span class="headingEndMark"> — </span>Class I disease may remain subclinical, regress either spontaneously or with antiparasitic treatment, or progress by transformation into other classes depending upon the presence of coinfections (ie, transformation into class II or VI), the presence of hepatic fibrosis (ie, transformation into class III or IV), or presence of certain genetic polymorphisms [<a href="#rid2">2</a>].</p><p>Class I schistosomal glomerular disease, particularly in the presence of living ova in stools or rectal snip, should be treated by <a class="drug drug_general" data-topicid="9805" href="/d/drug information/9805.html" rel="external">praziquantel</a> [<a href="#rid52">52</a>] or an alternative in resistant cases. Treatment of schistosomiasis, including its use in pregnant women, is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H15644894"><span class="h2">Class II</span><span class="headingEndMark"> — </span>Class II disease is reversible with simultaneous treatment of schistosomiasis (with <a class="drug drug_general" data-topicid="9805" href="/d/drug information/9805.html" rel="external">praziquantel</a>) and <em>Salmonella</em> (with an antibiotic such as <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid49">49</a>], or <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid53">53</a>]). Therapy against <em>Salmonella</em> alone is <strong>not</strong> effective, since these bacteria firmly attach to the schistosomal worms and hide under a protective layer of host proteins that covers the worms [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H15644988"><span class="h2">Classes III to V</span><span class="headingEndMark"> — </span>These classes of the disease progress relentlessly to end-stage kidney disease (ESKD) over four to six years in 37 to 75 percent of cases, regardless of therapy [<a href="#rid14">14,42,54</a>]. However, active schistosomal infection should be treated with an antiparasitic, although such therapy is unlikely to improve kidney disease. Immunosuppressive drugs are not indicated. The effect of antiinflammatory and investigational therapies that are used for the treatment of secondary amyloidosis (class V disease) is unknown in patients with schistosomiasis. (See  <a class="medical medical_review" href="/d/html/5588.html" rel="external">"Treatment of AA (secondary) amyloidosis"</a>.)</p><p class="headingAnchor" id="H2351877840"><span class="h2">Class VI</span><span class="headingEndMark"> — </span>Patients with schistosomal and hepatitis C virus (HCV) coinfection who have severe mixed cryoglobulinemia syndrome should be treated similarly to other patients with mixed cryoglobulinemia, including the use of immunosuppression, if needed. Anti-HCV therapy should be provided according to the degree of kidney dysfunction [<a href="#rid55">55</a>] (see  <a class="medical medical_review" href="/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>). Although such patients are unlikely to have active parasitic infection at this stage, those with positive serology should receive antiparasitic treatment.</p><p class="headingAnchor" id="H3292918026"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H10841761"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Human schistosomiasis is caused by infection with <em>Schistosoma haematobium</em>, <em>S. mansoni</em>, <em>S. japonicum</em>, <em>S. mekongi</em>, or <em>S. intercalatum</em>. Schistosomiasis may produce a broad spectrum of glomerular pathology. Many cases are subclinical or resolve spontaneously. By contrast, persistent or progressive glomerular disease develops in approximately 10 to 15 percent of patients who usually have hepatic fibrosis due to chronic infection with <em>S. mansoni</em> (and occasionally <em>S. haematobium</em>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The immune response to the parasite appears to be important in the development of glomerulonephritis. The initial glomerular injury is thought to be a consequence of antigens released by schistosomal worms in the portal vein tributaries. However, progression to advanced pathological lesions and eventually glomerulosclerosis involves other disease mechanisms (even after effective antiparasitic treatment)  (<a class="graphic graphic_figure graphicRef88447" href="/d/graphic/88447.html" rel="external">figure 2</a>). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Asymptomatic and self-limited glomerular disease may be relatively common in patients with schistosomal infection. Symptomatic patients with schistosomal glomerulopathy most frequently present with nephrotic syndrome or nephrotic-nephritic syndrome, and such patients typically have hepatosplenic schistosomiasis with hepatic fibrosis resulting from <em>S. mansoni</em> infection. Less commonly, affected patients may have isolated non-nephrotic proteinuria with a normal glomerular filtration rate (GFR), acute glomerulonephritis, nephrotic syndrome in combination with systemic manifestations of <em>Salmonella</em> or HCV (eg, fever, arthralgias, muscle aches, rash), or end-stage kidney disease (ESKD). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Asymptomatic patients with incidentally discovered non-nephrotic proteinuria may recover with antiparasitic treatment. By contrast, most symptomatic patients will have progressive kidney disease and develop ESKD or die from other sequelae of hepatic fibrosis. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic classification </strong>– The African Association of Nephrology (AFRAN) has endorsed a classification of schistosomal glomerulopathies into five categories based upon the prevailing histopathological lesions; a sixth category has been subsequently appended to encompass the lesions associated with HCV coinfection  (<a class="graphic graphic_picture graphicRef88448" href="/d/graphic/88448.html" rel="external">picture 1</a>) (see <a class="local">'Histologic classification'</a> above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of schistosomal glomerulopathy begins with clinical suspicion in a patient presenting with kidney disease who has known <em>S. mansoni</em> infection, exposure to an endemic area, or clinical evidence of chronic hepatosplenic schistosomiasis. If the patient is not known to have schistosomiasis, schistosomal infection should be documented. Most patients with schistosomiasis and kidney disease should have a kidney biopsy. In addition, it is important to evaluate these patients for coinfection with <em>Salmonella</em> and HBV or HCV in endemic areas. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening </strong>– Patients with chronic hepatosplenic schistosomiasis and hepatic fibrosis are at high risk for developing glomerulopathy, even after effective antiparasitic therapy  (<a class="graphic graphic_figure graphicRef88447" href="/d/graphic/88447.html" rel="external">figure 2</a>). In patients with chronic hepatosplenic schistosomiasis who do not have known kidney disease, screening for kidney disease on an annual basis with urine dipstick testing (for proteinuria and hematuria) and a serum creatinine may identify individuals with schistosomal glomerulopathy. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis </strong>– Therapy for schistosomal glomerulopathy is treatment of the underlying helminthic infection and, if present, the bacterial or viral coinfection. Immunosuppressive therapy is not warranted in most patients. The prognosis varies according to the histologic class. (See <a class="local">'Therapy and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H666913869"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Rashad Barsoum, MD, FRCP, FRCPE (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barsoum RS. Urinary schistosomiasis: review. J Adv Res 2013; 4:453.</a></li><li><a class="nounderline abstract_t">Barsoum RS. Schistosomal glomerulopathies. Kidney Int 1993; 44:1.</a></li><li class="breakAll">Nessim I, Francis M, Abdel-Rahman H, et al. Tubular proteins (TP) in hepatosplenic schistosomiasis (HSS). Proceedings of the 2nd International Congress of Geographical Nephrology, Hurghada, Egypt, 1993.</li><li><a class="nounderline abstract_t">Duarte DB, Vanderlei LA, Bispo RK, et al. Renal function in hepatosplenic schistosomiasis--an assessment of renal tubular disorders. PLoS One 2014; 9:e115197.</a></li><li><a class="nounderline abstract_t">Dkhil MA, Khalil MF, Bauomy AA, et al. Efficacy of Gold Nanoparticles against Nephrotoxicity Induced by Schistosoma mansoni Infection in Mice. Biomed Environ Sci 2016; 29:773.</a></li><li><a class="nounderline abstract_t">Barsoum RS. Tropical parasitic nephropathies. Nephrol Dial Transplant 1999; 14 Suppl 3:79.</a></li><li><a class="nounderline abstract_t">Ezzat E, Osman RA, Ahmet KY, Soothill JF. The association between Schistosoma haematobium infection and heavy proteinuria. Trans R Soc Trop Med Hyg 1974; 68:315.</a></li><li class="breakAll">Ezzat E, Tohamy M, et al. Immunopathological study of glomerulonephritis associated with Schistosoma haematobium infection. In: Proceedings of the International Conference on Schistosomiasis, Cairo 1978. p.625.</li><li class="breakAll">Soliman M, Abdel-Salam E, et al. Schistosomiasis haematobium glomerulopathy: a clinical or a pathological entity?. In: Abstracts of the 10th International Congress of Nephrology, London 1987. p.362.</li><li><a class="nounderline abstract_t">Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) 2012; 2:209.</a></li><li><a class="nounderline abstract_t">Sobh MA, Moustafa FE, el-Housseini F, et al. Schistosomal specific nephropathy leading to end-stage renal failure. Kidney Int 1987; 31:1006.</a></li><li><a class="nounderline abstract_t">Nussenzveig I, De Brito T, Carneiro CR, Silva AM. Human Schistosoma mansoni-associated glomerulopathy in Brazil. Nephrol Dial Transplant 2002; 17:4.</a></li><li><a class="nounderline abstract_t">Dos-Santos WLC, Sweet GMM, Azevêdo LG, et al. Current distribution pattern of biopsy-proven glomerular disease in Salvador, Brazil, 40 years after an initial assessment. J Bras Nefrol 2017; 39:376.</a></li><li><a class="nounderline abstract_t">Neves PDMM, Jorge LB, Cavalcante LB, et al. Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes . Clin Nephrol 2020; 93:251.</a></li><li><a class="nounderline abstract_t">Houba V. Experimental renal disease due to schistosomiasis. Kidney Int 1979; 16:30.</a></li><li><a class="nounderline abstract_t">Eid RA, Al-Shraim M, El-Sayed F, Radad K. Ultrastructural changes of kidney in Schistosoma mansoni-infected mice. Ultrastruct Pathol 2017; 41:320.</a></li><li><a class="nounderline abstract_t">Hoshino-Shimizu S, De Brito T, Kanamura HY, et al. Human schistosomiasis: Schistosoma mansoni antigen detection in renal glomeruli. Trans R Soc Trop Med Hyg 1976; 70:492.</a></li><li><a class="nounderline abstract_t">Barsoum RS, Bassily S, Baligh OK, et al. Renal disease in hepatosplenic schistosomiasis: a clinicopathological study. Trans R Soc Trop Med Hyg 1977; 71:387.</a></li><li><a class="nounderline abstract_t">Barsoum R. The changing face of schistosomal glomerulopathy. Kidney Int 2004; 66:2472.</a></li><li><a class="nounderline abstract_t">Barsoum RS, Sersawy G, Haddad S, et al. Hepatic macrophage function in schistosomal glomerulopathy. Nephrol Dial Transplant 1988; 3:612.</a></li><li><a class="nounderline abstract_t">Hillyer GV. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of hamsters and man infected with schistosomes. Proc Soc Exp Biol Med 1971; 136:880.</a></li><li><a class="nounderline abstract_t">Abdel Aziz N, Musaigwa F, Mosala P, et al. Type 2 immunity: a two-edged sword in schistosomiasis immunopathology. Trends Immunol 2022; 43:657.</a></li><li><a class="nounderline abstract_t">Sobhy E, Ali MI, et al. B-lymphocyte subpopulations in schitosomal glomerulopathy. Med J Cairo Univ 2001; 69:507.</a></li><li><a class="nounderline abstract_t">Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2:499.</a></li><li><a class="nounderline abstract_t">Abdel-Badie I, Barsoum RS. B-lymphocyte immunoglobulin surface expression in schistosomal glomerulopathy. Med J Ahmed Maher Hosp 1999; 1:1.</a></li><li><a class="nounderline abstract_t">Barsoum R, Nabil M, Saady G, et al. Immunoglobulin-A and the pathogenesis of schistosomal glomerulopathy. Kidney Int 1996; 50:920.</a></li><li><a class="nounderline abstract_t">Gonçalves FO, Fontes TM, Canuto AP. Schistosoma mansoni associated glomerulopathy with IgA mesangial deposits: case report. J Bras Nefrol 2017; 39:86.</a></li><li><a class="nounderline abstract_t">Kayange NM, Smart LR, Downs JA, et al. The influence of HIV and schistosomiasis on renal function: a cross-sectional study among children at a hospital in Tanzania. PLoS Negl Trop Dis 2015; 9:e0003472.</a></li><li><a class="nounderline abstract_t">Barsoum RS. Parasitic kidney disease: milestones in the evolution of our knowledge. Am J Kidney Dis 2013; 61:501.</a></li><li><a class="nounderline abstract_t">Isnard A, Chevillard C. Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis. Curr Genomics 2008; 9:290.</a></li><li><a class="nounderline abstract_t">McManus DP, Ross AG, Williams GM, et al. HLA class II antigens positively and negatively associated with hepatosplenic schistosomiasis in a Chinese population. Int J Parasitol 2001; 31:674.</a></li><li><a class="nounderline abstract_t">Hafez MH, Zaatar M, et al. HLA A1, B35, DR 1,4 and nephrotic syndrome in adult Egyptians. Med J Cairo Univ 1991; 59:947.</a></li><li><a class="nounderline abstract_t">Lopes AA, Port FK, James SA, et al. Race and glomerulonephritis in patients with and without hepatosplenic Schistosomiasis mansoni. Clin Nephrol 2002; 58:333.</a></li><li><a class="nounderline abstract_t">Neves PD, Bridi RA, Ramalho JA, et al. Schistosoma mansoni infection as a trigger to collapsing glomerulopathy in a patient with high-risk APOL1 genotype. PLoS Negl Trop Dis 2020; 14:e0008582.</a></li><li><a class="nounderline abstract_t">Barsoum RS. Schistosomal glomerulopathy: selection factors. Nephrol Dial Transplant 1987; 2:488.</a></li><li><a class="nounderline abstract_t">Abensur H, Nussenzveig I, Saldanha LB, et al. Nephrotic syndrome associated with hepatointestinal schistosomiasis. Rev Inst Med Trop Sao Paulo 1992; 34:273.</a></li><li><a class="nounderline abstract_t">el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. Semin Oncol 2001; 28:174.</a></li><li><a class="nounderline abstract_t">Mhimbira F, Hella J, Said K, et al. Prevalence and clinical relevance of helminth co-infections among tuberculosis patients in urban Tanzania. PLoS Negl Trop Dis 2017; 11:e0005342.</a></li><li><a class="nounderline abstract_t">Anchang-Kimbi JK, Elad DM, Sotoing GT, Achidi EA. Coinfection with Schistosoma haematobium and Plasmodium falciparum and Anaemia Severity among Pregnant Women in Munyenge, Mount Cameroon Area: A Cross-Sectional Study. J Parasitol Res 2017; 2017:6173465.</a></li><li><a class="nounderline abstract_t">Degarege A, Degarege D, Veledar E, et al. Plasmodium falciparum Infection Status among Children with Schistosoma in Sub-Saharan Africa: A Systematic Review and Meta-analysis. PLoS Negl Trop Dis 2016; 10:e0005193.</a></li><li><a class="nounderline abstract_t">el-Hawey AM, Abou-Taleb SA, Mohamed NH, et al. A clinico-parasitological and immunological studies (sic) on concomitant mansoniasis and filariasis in Egypt. J Egypt Soc Parasitol 1986; 16:95.</a></li><li><a class="nounderline abstract_t">Ott BR, Libbey NP, Ryter RJ, Trebbin WM. Treatment of schistosome-induced glomerulonephritis. A case report and review of the literature. Arch Intern Med 1983; 143:1477.</a></li><li><a class="nounderline abstract_t">Hsiao A, Toy T, Seo HJ, Marks F. Interaction between Salmonella and Schistosomiasis: A Review. PLoS Pathog 2016; 12:e1005928.</a></li><li><a class="nounderline abstract_t">Barnhill AE, Novozhilova E, Day TA, Carlson SA. Schistosoma-associated Salmonella resist antibiotics via specific fimbrial attachments to the flatworm. Parasit Vectors 2011; 4:123.</a></li><li><a class="nounderline abstract_t">Secor WE. Interactions between schistosomiasis and infection with HIV-1. Parasite Immunol 2006; 28:597.</a></li><li><a class="nounderline abstract_t">Neves PD, Bezerra KS, Silveira MA, et al. Schistosoma mansoni and membranous nephropathy. Kidney Int 2016; 89:959.</a></li><li><a class="nounderline abstract_t">Araújo SA, Neves PDMM, Wanderley DC, et al. The immunohistological profile of membranous nephropathy associated with chronic Schistosoma mansoni infection reveals a glomerulopathy with primary features. Kidney Int 2019; 96:793.</a></li><li><a class="nounderline abstract_t">Weerakoon KG, Gobert GN, Cai P, McManus DP. Advances in the Diagnosis of Human Schistosomiasis. Clin Microbiol Rev 2015; 28:939.</a></li><li><a class="nounderline abstract_t">Tsang VC, Wilkins PP. Immunodiagnosis of schistosomiasis. Immunol Invest 1997; 26:175.</a></li><li><a class="nounderline abstract_t">Qian Z, Lu P, Wang Z, et al. Isolation and specific detection of two major schistosoma gut-associated circulating antigens. Chin Med J (Engl) 2001; 114:614.</a></li><li><a class="nounderline abstract_t">Dash SC, Bhowmik D. Glomerulopathy with liver disease: patterns and management. Saudi J Kidney Dis Transpl 2000; 11:414.</a></li><li><a class="nounderline abstract_t">Mahmoud AA. Praziquantel for the treatment of helminthic infections. Adv Intern Med 1987; 32:193.</a></li><li><a class="nounderline abstract_t">Bassily S, Farid Z, Barsoum RS, et al. Renal biopsy in Schistosoma-Salmonella associated nephrotic syndrome. J Trop Med Hyg 1976; 79:256.</a></li><li><a class="nounderline abstract_t">Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989; 35:1227.</a></li><li><a class="nounderline abstract_t">Barsoum RS, William EA, Khalil SS. Hepatitis C and kidney disease: A narrative review. J Adv Res 2017; 8:113.</a></li></ol></div><div id="topicVersionRevision">Topic 3057 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25685452" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Urinary schistosomiasis: review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355449" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Schistosomal glomerulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355449" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Schistosomal glomerulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25531759" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Renal function in hepatosplenic schistosomiasis--an assessment of renal tubular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27998383" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Efficacy of Gold Nanoparticles against Nephrotoxicity Induced by Schistosoma mansoni Infection in Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10382987" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tropical parasitic nephropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4417931" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The association between Schistosoma haematobium infection and heavy proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4417931" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The association between Schistosoma haematobium infection and heavy proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4417931" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The association between Schistosoma haematobium infection and heavy proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018935" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chapter 10: Immunoglobulin A nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3108566" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Schistosomal specific nephropathy leading to end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773451" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human Schistosoma mansoni-associated glomerulopathy in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29319763" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Current distribution pattern of biopsy-proven glomerular disease in Salvador, Brazil, 40 years after an initial assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32228829" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/119088" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Experimental renal disease due to schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796565" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ultrastructural changes of kidney in Schistosoma mansoni-infected mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/65811" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Human schistosomiasis: Schistosoma mansoni antigen detection in renal glomeruli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/595092" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal disease in hepatosplenic schistosomiasis: a clinicopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569345" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The changing face of schistosomal glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3146717" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatic macrophage function in schistosomal glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4995331" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of hamsters and man infected with schistosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35835714" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Type 2 immunity: a two-edged sword in schistosomiasis immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : B-lymphocyte subpopulations in schitosomal glomerulopathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12094224" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The immunobiology of schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : B-lymphocyte immunoglobulin surface expression in schistosomal glomerulopathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8872967" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunoglobulin-A and the pathogenesis of schistosomal glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28355401" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Schistosoma mansoni associated glomerulopathy with IgA mesangial deposits: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612312" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The influence of HIV and schistosomiasis on renal function: a cross-sectional study among children at a hospital in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23337800" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Parasitic kidney disease: milestones in the evolution of our knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19471606" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11336748" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : HLA class II antigens positively and negatively associated with hepatosplenic schistosomiasis in a Chinese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : HLA A1, B35, DR 1,4 and nephrotic syndrome in adult Egyptians</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12425482" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Race and glomerulonephritis in patients with and without hepatosplenic Schistosomiasis mansoni.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33119586" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Schistosoma mansoni infection as a trigger to collapsing glomerulopathy in a patient with high-risk APOL1 genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3126449" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Schistosomal glomerulopathy: selection factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1342083" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nephrotic syndrome associated with hepatointestinal schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301380" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bladder cancer in Africa: update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28178325" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevalence and clinical relevance of helminth co-infections among tuberculosis patients in urban Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28168042" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Coinfection with Schistosoma haematobium and Plasmodium falciparum and Anaemia Severity among Pregnant Women in Munyenge, Mount Cameroon Area: A Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27926919" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Plasmodium falciparum Infection Status among Children with Schistosoma in Sub-Saharan Africa: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A clinico-parasitological and immunological studies (sic) on concomitant mansoniasis and filariasis in Egypt</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6870421" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of schistosome-induced glomerulonephritis. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27907208" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interaction between Salmonella and Schistosomiasis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21711539" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Schistosoma-associated Salmonella resist antibiotics via specific fimbrial attachments to the flatworm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17042931" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interactions between schistosomiasis and infection with HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26994579" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Schistosoma mansoni and membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31445585" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The immunohistological profile of membranous nephropathy associated with chronic Schistosoma mansoni infection reveals a glomerulopathy with primary features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224883" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Advances in the Diagnosis of Human Schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037622" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Immunodiagnosis of schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11780438" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Isolation and specific detection of two major schistosoma gut-associated circulating antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209333" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Glomerulopathy with liver disease: patterns and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3548250" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Praziquantel for the treatment of helminthic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/827621" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Renal biopsy in Schistosoma-Salmonella associated nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2504987" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28149647" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatitis C and kidney disease: A narrative review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
